Neuroleptic malignant syndrome: Mechanisms, interactions, and causality

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1780-1790

  Gillman, P Ken ^a  

^a PsychoTropical Research   (Australia)

Author keywords

Causality; Hyperthermia; Morbidity; Neuroleptic malignant syndrome; Neuroleptics

Indexed keywords

ACETYLCHOLINE; APOMORPHINE; ATRACURIUM; ATROPINE; BROMOCRIPTINE; DOPAMINE; PHYSOSTIGMINE; PROMETHAZINE; SCOPOLAMINE; TETRABENAZINE;

BODY TEMPERATURE MEASUREMENT; CELL MEMBRANE; FEVER; HILL REACTION; HUMAN; MALIGNANT HYPERTHERMIA; MEDICINE; MITOCHONDRION; MORBIDITY; MORTALITY; NERVE CELL; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK; TEMPERATURE SENSITIVITY; THERMOREGULATION;

ANTIPSYCHOTIC AGENTS; FEVER; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 77956624798     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23220     Document Type: Review

References (156)

1. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses]. Ann Med Psychol (Paris) 1960;118:145-152.
2. Preston J. Central nervous system reactions to small doses of tranquilizers; report of one death. Am Pract Digest Treat 1959;10:627-630.
3. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res 2005;135:249-256. (Pubitemid 40984616)
4. Kaufman KR, Levitt MJ, Schiltz JF, Sunderram J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann Clin Psychiatry 2006;18:201-204.
5. Lee JW. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry 2007;19:9-16.
6. Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry 2007;48:205-211.
7. Factor SA, Santiago A. Parkinsonism-hyperpyrexia syndrome in Parkinson's disease. In: Frucht SJ, Fahn S, editors. Movement disorder emergencies: diagnosis and treatment. Totowa: Humana Press Inc; 2005. p 29-40.
8. Factor SA. Neuroleptic malignant syndrome. In: Factor SA, Lang AE, Weiner WJ, editors. Drug induced movement disorders. New York: Blackwell Publishing; 2005. p 174-212.
9. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-876.
10. Reulbach U, Dutsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007;11:413.
11. Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord 2005;20:322-334.
12. Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999;2:129-144.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington: APA; 1994.
14. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997;154:1156-1158.
15. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143:1227-1233.
16. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986;143:1587-1590. (Pubitemid 17196204)
17. Caroff SN. Neuroleptic malignant syndrome. In: Mann SC, Caroff SN, Keck PE, Lazarus A, editors. Neuroleptic malignant syndrome and related conditions. Second ed. Washington: American Psychiatric Publishing; 2003. p 1-44.
18. Caroff S, Caroff SN, Mann SC, Campbell EC, Sullivan KA, Obeso J. Neuroleptic malignant syndrome. In: Frucht SJ, Fahn S, editors. Current clinical neurology: movement disorder emergencies: diagnosis and treatment. Totowa: Humana Press Inc; 2005. p 41-51.
19. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-180. (Pubitemid 29077106)
20. Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994;182:168-173.
21. Adityanjee SM, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005;28:197-204.
22. Tanii H, Taniguchi N, Niigawa H, et al. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. Brain Res 1996;743:263-270.
23. Parada MA, de Parada MP, Rada P, Hernandez L. Sulpiride increases and dopamine decreases intracranial temperature in rats when injected in the lateral hypothalamus: an animal model for the neuroleptic malignant syndrome? Brain Res 1995;674:117-121.
24. Keck PE Jr, Seeler DC, Pope HG Jr, McElroy SL. Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome? Biol Psychiatry 1990;28:58-62.
25. Folk GE Jr, Semken HA Jr. The evolution of sweat glands. Int J Biometeorol 1991;35:180-186.
26. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;338:149-151.
27. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454. (Pubitemid 29084777)
28. Weiss G, Bogdan C, Hentze MW. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J Immunol 1997;158:420-425.
29. Rosebush PI, Anglin RE, Richards C, Mazurek MF. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol 2008;28:459-461.
30. Hsiao AL, Baker MD. Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children. Curr Opin Pediatr 2005;17:56-61.
31. Mackowiak PA. Concepts of fever. Arch Intern Med 1998;158:1870-1881.
32. Kiyatkin EA. Brain hyperthermia as physiological and pathological phenomena. Brain Res Brain Res Rev 2005;50:27-56.
33. Vinkers CH, Groenink L, van Bogaert MJ, et al. Stress-induced hyperthermia and infection-induced fever: two of a kind? Physiol Behav 2009;98:37-43.
34. Bouwknecht JA, Olivier B, Paylor RE. The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci Biobehav Rev 2007;31:41-59.
35. Prosser CL. Environmental and metabolic animal physiology. Fourth ed. New York: Wiley-Liss; 1991.
36. Timmerman RJ, Thompson J, Noordzij HM, van der Meer JW. Psychogenic periodic fever. Neth J Med 1992;41:158-160.
37. Oka T, Oka K, Hori T. Mechanisms and mediators of psychological stress-induced rise in core temperature. Psychosom Med 2001;63:476-486. (Pubitemid 32467123)
38. Noakes TD, Dugasa JP, Dugasa LR, et al. Body temperatures during three long-distance polar swims in water of 0-3°C. J Therm Biol 2009;34:23-31.
39. O'Grady NP, Barie PS, Bartlett JG, et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008;36:1330-1349.
40. Torossian A. Survey on intraoperative temperature management in Europe. Eur J Anaesthesiol 2007;24:668-675.
41. Sessler DI. Temperature monitoring and perioperative thermoregulation. Anesthesiology 2008;109:318-338.
42. Ganio MS, Brown CM, Casa DJ, et al. Validity and reliability of devices that assess body temperature during indoor exercise in the heat. J Athl Train 2009;44:124-135.
43. Hooper VD, Andrews JO. Accuracy of noninvasive core temperature measurement in acutely ill adults: the state of the science. Biol Res Nurs 2006;8:24-34.
44. Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. Arch Intern Med 2007;167:2170-2176.
45. Dematte JE, O'Mara K, Buescher J, et al. Near-fatal heat stroke during the 1995 heat wave in Chicago. Ann Intern Med 1998;129:173-181.
46. Sharma HS, Kiyatkin EA. Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J Chem Neuroanat 2009;37:18-32.
47. Hausfater P, Hurtado M, Pease S, et al. Is procalcitonin a marker of critical illness in heatstroke? Intensive Care Med 2008;34:1377-1383.
48. Yaqub B, Al Deeb S. Heat strokes: aetiopathogenesis, neurological characteristics, treatment and outcome. J Neurol Sci 1998;156:144-151.
49. Cremer OL, Kalkman CJ. Cerebral pathophysiology and clinical neurology of hyperthermia in humans. Prog Brain Res 2007;162:153-169.
50. Baena RC, Busto R, Dietrich WD, Globus MY, Ginsberg MD. Hyperthermia delayed by 24 hours aggravates neuronal damage in rat hippocampus following global ischemia. Neurology 1997;48:768-773.
51. Willis WT, Jackman MR, Bizeau ME, Pagliassotti MJ, Hazel JR. Hyperthermia impairs liver mitochondrial function in vitro. Am J Physiol Regul Integr Comp Physiol 2000;278:R1240-R1246.
52. Iwagami Y. Changes in the ultrastructure of human cells related to certain biological responses under hyperthermic culture conditions. Hum Cell 1996;9:353-366.
53. Lepock JR. Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage. Int J Hyperthermia 2003;19:252-266.
54. Sharma HS, Hoopes PJ. Hyperthermia induced pathophysiology of the central nervous system. Int J Hyperthermia 2003;19:325-354. (Pubitemid 36740801)
55. Kiyatkin EA. Brain temperature fluctuations during physiological and pathological conditions. Eur J Appl Physiol 2007;101:3-17.
56. Rossi S, Zanier ER, Mauri I, Columbo A, Stocchetti N. Brain temperature, body core temperature, and intracranial pressure in acute cerebral damage. J Neurol Neurosurg Psychiatry 2001;71:448-454.
57. Cheung SS, McLellan TM, Tenaglia S. The thermophysiology of uncompensable heat stress. Physiological manipulations and individual characteristics. Sports Med 2000;29:329-359.
58. Sessler DI. Thermoregulatory defense mechanisms. Crit Care Med 2009;37(7 Suppl):S203-S210.
59. Carter R III, Cheuvront SN, Sawka MN. A case report of idiosyncratic hyperthermia and review of U.S. Army heat stroke hospitalizations. J Sport Rehabil 2007;16:238-243.
60. Carter R III. Heat related illness. Sport Sci Exchange 2006;19:1-6.
61. Carter R. Exertional heat illness and hyponatremia: an epidemiological prospective. Curr Sports Med Rep 2008;7:s20-s27.
62. Torline RL. Extreme hyperpyrexia associated with central anticholinergic syndrome. Anesthesiology 1992;76:470-471.
63. Deschamps A, Levy RD, Cosio MG, Marliss EB, Magder S. Effect of saline infusion on body temperature and endurance during heavy exercise. J Appl Physiol 1989;66:2799-2804.
64. Knochel JP, Reed G. Disorders of heat regulation. In: Narins RG, editor. Maxwell & Kleeman's clinical disorders of fluid and electrolyte metabolism. Fifth ed. New York: McGraw-Hill; 1994. p 1549-1590.
65. Guyton AC. Textbook of medical physiology. London: Saunders; 1986.
66. Harker J, Gibson P. Heat-stroke: a review of rapid cooling techniques. Intensive Crit Care Nurs 1995;11:198-202.
67. Hubbard RW. Heatstroke pathophysiology: the energy depletion model. Med Sci Sports Exerc 1990;22:19-28.
68. Detry JM, Brengelmann GL, Rowell LB, Wyss C. Skin and muscle components of forearm blood flow in directly heated resting man. J Appl Physiol 1972;32:506-511.
69. Rowell LB, Brengelmann GL, Murray JA. Cardiovascular responses to sustained high skin temperature in resting man. J Appl Physiol 1969;27:673-680.
70. Kenney WL. Human cardiovascular responses to passive heat stress. J Physiol 2008;586:3.
71. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000;99:27-35.
72. Patel RJ, Saylor T, Williams SR, Clark RF. Prevalence of autonomic signs and symptoms in antimuscarinic drug poisonings. J Emerg Med 2004;26:89-94. (Pubitemid 38147525)
73. Page CB, Duffull SB, Whyte IM, Isbister GK. Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal. QJM 2009;102:123-131.
74. Cox B, Kerwin R, Lee TF. Dopamine receptors in the central thermoregulatory pathways of the rat. J Physiol 1978;282:471-483.
75. Perachon S, Betancur C, Pilon C, Rostene W, Schwartz JC, Sokoloff P. Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport 2000;11:221-225.
76. Vincent SG, Waddell AE, Caron MG, Walker JK, Fisher JT. A murine model of hyperdopaminergic state displays altered respiratory control. FASEB J 2007;21:1463-1471.
77. Cussac D, Boutet-Robinet E, Ailhaud MC, et al. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 2008;594:32-38.
78. Gerbershagen MU, Wappler F, Fiege M, et al. Effects of a 5HT(2) receptor agonist on anaesthetized pigs susceptible to malignant hyperthermia. Br J Anaesth 2003;91:281-284.
79. Sharma HS, Westman J, Nyberg F, Cervos-Navarro J, Dey PK. Role of serotonin and prostaglandins in brain edema induced by heat stress. An experimental study in the young rat. Acta Neurochir Suppl (Wien) 1994;60:65-70.
80. Chang CP, Chen SH, Lin MT. Ipsapirone and ketanserin protects against circulatory shock, intracranial hypertension, and cerebral ischemia during heatstroke. Shock 2005;24:336-340.
81. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991;159:709-712.
82. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998;12:482-491.
83. Morris E, Green D, Graudins A. Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. J Med Toxicol 2009;5:24-26.
84. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002;303:815-822.
85. Pierantozzi M, Sabato AF, Leonardis F, et al. Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes. Exp Brain Res 2000;133:368-376.
86. Pires W, Wanner SP, La Guardia RB, et al. Intracerebroventricular physostigmine enhances blood pressure and heat loss in running rats. J Physiol Pharmacol 2007;58:3-17.
87. Wanner SP, Guimaraes JB, Rodrigues LO, Marubayashi U, Coimbra CC, Lima NR. Muscarinic cholinoceptors in the ventromedial hypothalamic nucleus facilitate tail heat loss during physical exercise. Brain Res Bull 2007;73:28-33. (Pubitemid 46722656)
88. Gomeza J, Shannon H, Kostenis E, et al. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999;96:1692-1697.
89. Martin-Latry K, Goumy MP, Latry P, et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry 2007;22:335-338.
90. Peterson G, Jackson S, Naunton M, Gillman PK. Beware of anticholinergics in the elderly: delirious dangers of the deadly nightshade. J Pharm 2006;25:882-884.
91. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008;56:1333-1341.
92. Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000;35:374-381.
93. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72:325-336. (Pubitemid 33743589)
94. Dhib-Jalbut S, Hesselbrock R, Mouradian MM, Means ED. Bromocriptine treatment of neuroleptic malignant syndrome. J Clin Psychiatry 1987;48:69-73.
95. Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome. Successful treatment with bromocriptine. JAMA 1983;249:386-388.
96. Goekoop JG, Carbaat PA. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 1982;2:49-50.
97. Goulon M, de Rohan-Chabot P, Elkharrat D, Gajdos P, Bismuth C, Conso F. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. Neurology 1983;33:516-518.
98. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83.
99. Mann SC, Caroff SN, Fricchione G, Campbell EC. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 2000;30:363-374.
100. Caroff SN, Mann SC, Keck PE, Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiat 1998;44:378-381.
101. Di Rosa AE, Morgante L, Coraci MA, et al. Functional hyperthermia due to central dopaminergic impairment. Funct Neurol 1988;3:211-215.
102. Spivak B, Maline DI, Kozyrev VN, et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry 2000;15:330-333.
103. Patel P, Bristow G. Postoperative neuroleptic malignant syndrome. A case report. Can J Anaesth 1987;34:515-518. (Pubitemid 18022310)
104. Sangal R, Dimitrijevic R. Neuroleptic malignant syndrome. Successful treatment with pancuronium. JAMA 1985;254:2795-2796.
105. Morris HH III, McCormick WF, Reinarz JA. Neuroleptic malignant syndrome. Arch Neurol 1980;37:462-463.
106. Rosenbaum HK, Miller JD. Malignant hyperthermia and myotonic disorders. Anesthesiol Clin North America 2002;20:623-664.
107. Vogt S, Heinrich L, Schumacher YO, et al. Power output during stage racing in professional road cycling. Med Sci Sports Exerc 2006;38:147-151.
108. Davies CT. Effect of air resistance on the metabolic cost and performance of cycling. Eur J Appl Physiol Occup Physiol 1980;45:245-254.
109. Roewer N, Dziadzka A, Greim CA, Kraas E, Schulte am Esch J. Cardiovascular and metabolic responses to anesthetic-induced malignant hyperthermia in swine. Anesthesiology 1995;83:141-159.
110. Gronert GA, Milde JH, Theye RA. Dantrolene in porcine malignant hyperthermia. Anesthesiology 1976;44:488-495.
111. Thomas A, Onofrj M. Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. Mov Disord 2005;20:1671.
112. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001;16:960-962.
113. Toru M, Matsuda O, Makiguchi K, Sugano K. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981;169:324-327.
114. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985;254:2792-2795.
115. Pfeiffer RF, Sucha EL. "On-off"-induced lethal hyperthermia. Mov Disord 1989;4:338-341.
116. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or - dopaminergic malignant syndrome - due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord 2003;9:175-178.
117. Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 1991;151:794-796.
118. Sundal E. [Akinetic crisis - a possible form of parkinsonism]. Dtsch Med Wochenschr 1977;102:70.
119. Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology 2005;64:1162-1169.
120. Danielczyk W. [Therapy of akinetic crises]. Med Welt 1973;24:1278-1282.
121. Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003;9 (Suppl 1):S31-S41. (Pubitemid 36539391)
122. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-197. (Pubitemid 46374760)
123. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27:230-233.
124. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-394. (Pubitemid 18083674)
125. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008;31:313-318.
126. Petzinger GM, Bressman SB. A case of tetrabenazine induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12:246-248.
127. Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 1998;24:369-371.
128. Login IS, Cronin MJ, MacLeod RM. Neuroleptic malignant syndrome caused by dopamine depleting drugs. Neurology 1982;32:218-219.
129. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996;11:95.
130. Keck PE Jr, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy? J Neuropsychiatry Clin Neurosci 1995;7:135-144.
131. Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975;47:62-65.
132. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:1-14.
133. Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009;109:1065-1069.
134. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010;110:498-507.
135. Carpenter D, Robinson RL, Quinnell RJ, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009;103:538-548.
136. Neppe VM. The neuroleptic malignant syndrome. A priority system. S Afr Med J 1984;65:523-525.
137. Kellam AM. The neuroleptic malignant syndrome, so-called. A survey of the world literature. Br J Psychiatry 1987;150:752-759.
138. Kellam AM. The (frequently) neuroleptic (potentially) malignant syndrome. Br J Psychiatry 1990;157:169-173.
139. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'. Arch Gen Psychiatry 1986;43:839-848.
140. Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:425-443.
141. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
142. Perrio M, Voss S, Shakir SA. Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf 2007;30:333-346. (Pubitemid 46624532)
143. Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 2008;118:337-346.
144. Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 2002;25:467-471.
145. van Reekum R, Streiner DL, Conn DK. Applying Bradford Hill's criteria for causation to neuropsychiatry: challenges and opportunities. J Neuropsychiatry Clin Neurosci 2001;13:318-325.
146. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989;50:295-298.
147. Douglas A, Morris J. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease. Age Ageing 2006;35:640-641.
148. Lattanzi L, Mungai F, Romano A, Bonuccelli U, Cassano GB, Fagiolini A. Subcutaneous apomorphine for neuroleptic malignant syndrome. Am J Psychiatry 2006;163:1450-1451. (Pubitemid 44464425)
149. Wang HC, Hsieh Y. Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord 2001;16:765-767.
150. Bonuccelli U, Piccini P, Corsini GU, Muratorio A. Apomorphine in malignant syndrome due to levodopa withdrawal. Ital J Neurol Sci 1992;13:169-170.
151. Simonetto M, Ferigo L, Zanet L, et al. Acute akinesia, an unusual complication in Parkinson's disease: a case report. Neurol Sci 2008;29:181-183.
152. Gillman PK. In response to Morris et al. Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. J Med Toxicol 2009;5:259.
153. Galiana G, Branca RT, Jenista ER, Warren WS. Accurate temperature imaging based on intermolecular coherences in magnetic resonance. Science 2008;322:421-424.
154. Rieke V, Butts Pauly K. MR thermometry. J Magn Reson Imaging 2008;27:376-390.
155. Marshall I, Karaszewski B, Wardlaw JM, et al. Measurement of regional brain temperature using proton spectroscopic imaging: validation and application to acute ischemic stroke. Magn Reson Imaging 2006;24:699-706.
156. Gant N, Atkinson G, Williams C. The validity and reliability of intestinal temperature during intermittent running. Med Sci Sports Exerc 2006;38:1926-1931. (Pubitemid 44707796)